PURPOSE: To determine the relationships between visual function and ganglion cell and inner plexiform layer thickness and neuropsychological measures in multiple sclerosis (MS). METHODS: Ninety-five relapsing-remitting MS (RRMS) and 36 progressive MS patients underwent 100%-contrast visual acuity (VA), 2.5%- and 1.25%-contrast letter acuity (LA) testing, Cirrus-HD-optical coherence tomography, and neuropsychological assessments. Mixed-effects regression models were used to assess relationships. RESULTS: Across the cohort, 1.25%-contrast LA was associated with Symbol Digit Modalities Test (SDMT; β = 2.17, p = 0.005) and Brief Visuospatial Memory Test-Revised (BVMT-R) total recall (TR) and delayed recall (DR) scores (β = 0.31, p < 0.001; β = 0.15, p = 0.039, respectively). 2.5%-contrast LA was associated with BVMT-R TR scores (β = 0.27, p = 0.006). In the RRMS cohort, 1.25%-contrast LA was generally more significantly associated with cognitive measures: SDMT (β = 2.97, p = 0.001) and BVMT-R TR (β = 0.32, p < 0.001) and DR (β = 0.22, p = 0.012). CONCLUSION: This study suggests that visual pathway measures, particularly visual function measures, reflect aspects of cognitive function in MS, further supporting their roles as complementary outcomes in MS neuroprotection trials.
PURPOSE: To determine the relationships between visual function and ganglion cell and inner plexiform layer thickness and neuropsychological measures in multiple sclerosis (MS). METHODS: Ninety-five relapsing-remitting MS (RRMS) and 36 progressive MS patients underwent 100%-contrast visual acuity (VA), 2.5%- and 1.25%-contrast letter acuity (LA) testing, Cirrus-HD-optical coherence tomography, and neuropsychological assessments. Mixed-effects regression models were used to assess relationships. RESULTS: Across the cohort, 1.25%-contrast LA was associated with Symbol Digit Modalities Test (SDMT; β = 2.17, p = 0.005) and Brief Visuospatial Memory Test-Revised (BVMT-R) total recall (TR) and delayed recall (DR) scores (β = 0.31, p < 0.001; β = 0.15, p = 0.039, respectively). 2.5%-contrast LA was associated with BVMT-R TR scores (β = 0.27, p = 0.006). In the RRMS cohort, 1.25%-contrast LA was generally more significantly associated with cognitive measures: SDMT (β = 2.97, p = 0.001) and BVMT-R TR (β = 0.32, p < 0.001) and DR (β = 0.22, p = 0.012). CONCLUSION: This study suggests that visual pathway measures, particularly visual function measures, reflect aspects of cognitive function in MS, further supporting their roles as complementary outcomes in MS neuroprotection trials.
Authors: Ralph H B Benedict; Diane Cookfair; Rebecca Gavett; Mark Gunther; Frederick Munschauer; Neeta Garg; Bianca Weinstock-Guttman Journal: J Int Neuropsychol Soc Date: 2006-07 Impact factor: 2.892
Authors: Shiv Saidha; Stephanie B Syc; Mohamed A Ibrahim; Christopher Eckstein; Christina V Warner; Sheena K Farrell; Jonathan D Oakley; Mary K Durbin; Scott A Meyer; Laura J Balcer; Elliot M Frohman; Jason M Rosenzweig; Scott D Newsome; John N Ratchford; Quan D Nguyen; Peter A Calabresi Journal: Brain Date: 2011-01-20 Impact factor: 13.501
Authors: Shiv Saidha; Omar Al-Louzi; John N Ratchford; Pavan Bhargava; Jiwon Oh; Scott D Newsome; Jerry L Prince; Dzung Pham; Snehashis Roy; Peter van Zijl; Laura J Balcer; Elliot M Frohman; Daniel S Reich; Ciprian Crainiceanu; Peter A Calabresi Journal: Ann Neurol Date: 2015-10-01 Impact factor: 10.422
Authors: Shiv Saidha; Elias S Sotirchos; Jiwon Oh; Stephanie B Syc; Michaela A Seigo; Navid Shiee; Chistopher Eckstein; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Teresa C Frohman; Scott Newsome; John N Ratchford; Laura J Balcer; Dzung L Pham; Ciprian M Crainiceanu; Elliot M Frohman; Daniel S Reich; Peter A Calabresi Journal: JAMA Neurol Date: 2013-01 Impact factor: 18.302
Authors: J Toledo; J Sepulcre; A Salinas-Alaman; A García-Layana; M Murie-Fernandez; B Bejarano; P Villoslada Journal: Mult Scler Date: 2008-06-23 Impact factor: 6.312
Authors: S Schippling; L J Balk; F Costello; P Albrecht; L Balcer; P A Calabresi; J L Frederiksen; E Frohman; A J Green; A Klistorner; O Outteryck; F Paul; G T Plant; G Traber; P Vermersch; P Villoslada; S Wolf; A Petzold Journal: Mult Scler Date: 2014-06-16 Impact factor: 6.312
Authors: Prejaas Tewarie; Lisanne Balk; Fiona Costello; Ari Green; Roland Martin; Sven Schippling; Axel Petzold Journal: PLoS One Date: 2012-04-19 Impact factor: 3.240
Authors: James Nguyen; Alissa Rothman; Natalia Gonzalez; Ama Avornu; Esther Ogbuokiri; Laura J Balcer; Steven L Galetta; Elliot M Frohman; Teresa Frohman; Ciprian Crainiceanu; Peter A Calabresi; Shiv Saidha Journal: J Neuroophthalmol Date: 2019-12 Impact factor: 3.042
Authors: Olwen C Murphy; Ohemaa Kwakyi; Mustafa Iftikhar; Sidra Zafar; Jeffrey Lambe; Nicole Pellegrini; Elias S Sotirchos; Natalia Gonzalez-Caldito; Esther Ogbuokiri; Angeliki Filippatou; Hunter Risher; Norah Cowley; Sydney Feldman; Nicholas Fioravante; Elliot M Frohman; Teresa C Frohman; Laura J Balcer; Jerry L Prince; Roomasa Channa; Peter A Calabresi; Shiv Saidha Journal: Mult Scler Date: 2019-05-16 Impact factor: 6.312
Authors: Dejan Jakimovski; Ralph H B Benedict; Bianca Weinstock-Guttman; Osman Ozel; Tom A Fuchs; Norah Lincoff; Niels Bergsland; Michael G Dwyer; Robert Zivadinov Journal: J Neurol Date: 2021-02-15 Impact factor: 4.849
Authors: Arzu C Has Silemek; Jean-Philippe Ranjeva; Bertrand Audoin; Christoph Heesen; Stefan M Gold; Simone Kühn; Martin Weygandt; Jan-Patrick Stellmann Journal: Hum Brain Mapp Date: 2021-04-07 Impact factor: 5.038
Authors: Sara Collorone; Baris Kanber; Leen Hashem; Niamh Cawley; Ferran Prados; Indran Davagnanam; Frederik Barkhof; Olga Ciccarelli; Ahmed Toosy Journal: J Neuroophthalmol Date: 2021-09-23 Impact factor: 4.415